文献速递心脑血管急症重症综合管理与镇静镇痛

取栓后早期强化血压管理(IDENTIFY)研究方案:一项随机对照临床试验

Efficacy of Early Intensive Blood Pressure Management After Thrombectomy: Protocol for a Randomized Controlled Clinical Trial (IDENTIFY).
PubMed 文献 · Neurocrit Care · 2022-11-03
一句话结论IDENTIFY试验将验证前循环取栓成功再通后早期强化降压(目标<130 mmHg)能否降低90天依赖(mRS 3-6),方案见刊,结果待公布。

IDENTIFY是一项前瞻性、随机、开放标签、评估者设盲的多中心临床试验,计划纳入600例前循环急性缺血性卒中、发病6小时内完成血管内取栓并成功再通、取栓后6小时内连续两次血压>130 mmHg的患者,1:1随机分为强化管理组(目标血压<130 mmHg,收缩压<110 mmHg时停用降压药)与标准管理组(目标血压<180 mmHg,收缩压<140 mmHg时逐步减量至140 mmHg或停输)。主要终点为90天依赖率(改良Rankin量表评分3-6分),次要终点包括24小时和7天内脑出血、恶性脑水肿、全因死亡、90天死亡和严重残疾及生活质量,安全性终点包括24小时内卒中复发、早期神经功能恶化、低血压、取栓后7天内死亡及急性肾损伤。

要点

  • 纳入标准:前循环急性缺血性卒中、发病6小时内完成取栓、成功再通、取栓后6小时内连续两次血压>130 mmHg。
  • 强化组目标血压<130 mmHg,收缩压<110 mmHg时停用降压药;标准组目标<180 mmHg,收缩压<140 mmHg时逐步减量至140 mmHg或停输。
  • 随机后1小时内降压至目标范围,并维持至取栓后24小时,使用静脉降压药物。
  • 主要终点为90天依赖率(mRS 3-6分);样本量预计600例。
  • 试验注册于chictr.org.cn(注册号ChiCTR2200057770),注册日期2022年3月17日。

适用人群与场景

  • 前循环急性缺血性卒中患者,发病6小时内完成血管内取栓并成功再通。
  • 取栓后6小时内连续两次血压读数>130 mmHg。
  • 取栓结束即开始持续血压监测,转运至病房期间血压高的患者也可纳入。

诊断标准与关键阈值

  • 纳入标准:前循环急性缺血性卒中、发病6小时内取栓、成功再通、取栓后6小时内连续两次血压>130 mmHg。

处置流程与药物剂量

  • 强化管理组:目标血压<130 mmHg,收缩压<110 mmHg时停用降压药物。
  • 标准管理组:目标血压<180 mmHg,收缩压<140 mmHg时逐步减少降压药直至收缩压回升至140 mmHg或停止输注。
  • 随机后1小时内将血压降至目标范围,并维持至取栓后24小时,使用静脉降压药物。

研究设计与关键结果

  • 研究类型:前瞻性、随机、开放标签、评估者设盲的多中心临床试验。
  • 计划样本量600例,1:1随机分为强化管理组与标准管理组。
  • 主要终点:90天依赖率(改良Rankin量表评分3-6分)。
  • 次要终点:24小时和7天内脑出血(症状性或无症状性)、恶性脑水肿、全因死亡、90天死亡和严重残疾、90天生活质量(EQ-5D-5L和SF-36)。
  • 安全性终点:24小时内卒中复发、早期神经功能恶化、24小时内低血压、取栓后7天内死亡、全因急性肾损伤。

证据类型、等级与局限

  • 证据类型:随机对照临床试验方案。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该试验旨在比较取栓后早期强化血压管理(目标<130 mmHg)与标准管理(目标<180 mmHg)的疗效与安全性,结果将影响取栓后血压管理策略。

指南或共识出处

  • IDENTIFY研究方案,注册于chictr.org.cn(注册号ChiCTR2200057770),注册日期2022年3月17日。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The optimal strategy for blood pressure management after thrombectomy remains unknown. The primary objective of The Early Intensive Blood Pressure Management after Endovascular Thrombectomy (IDENTIFY) study is to explore the efficacy and safety of early intensive blood pressure management strategies after thrombectomy compared with that of standard management.

METHODS: The IDENTIFY study is a prospective, randomized, open-label, assessor-blinded multicenter clinical trial. Patients with acute anterior circulation ischaemic stroke who underwent endovascular thrombectomy within 6 h of stroke onset, achieved successful recanalization, and had two consecutive blood pressure readings > 130 mm Hg during the first 6 h after thrombectomy will be enrolled and centrally randomized into intensive or standard management groups in a 1:1 ratio. Continuous blood pressure monitoring will be initiated at the end of thrombectomy, and patients with high blood pressure during the transfer to the wards will also be enrolled. For patients in the intensive management group, the target blood pressure will be < 130 mm Hg, and the use of antihypertensive drugs will be discontinued if systolic blood pressure goes below 110 mm Hg. The target blood pressure for the standard management group will be < 180 mm Hg, and if systolic blood pressure decreases below 140 mm Hg, the use of antihypertensive drugs will be stepwise decreased until the systolic blood pressure reaches 140 mm Hg again or the infusion is discontinued. Patients will have their blood pressure reduced to the target range within 1 h from randomization and maintained until 24 h after thrombectomy with intravenous hypertensive drugs. A sample size of 600 was predicted. The primary outcome will be the rate of dependency (modified Rankin Scale scores 3-6) at 90 days. Secondary outcomes will include intracerebral hemorrhage (either symptomatic or asymptomatic) within 24 h and 7 days, malignant brain oedema, all-cause death, death and severe disability at 90 days, and quality of life at 90 days, which will be measured using the EuroQol-5 Dimensions-5 Level (EQ-5D-5L) and the 36-Item Short Form Health Survey (SF-36). Safety outcomes will include stroke recurrence within 24 h, early neurological deterioration, hypotension within 24 h, death within 7 days after endovascular thrombectomy, and all-cause acute kidney injury. Trial registration chictr.org.cn (identifier: ChiCTR2200057770). Registered March 17, 2022, http://www.chictr.org.cn/edit.aspx?pid=162575&htm=4.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Zhang X, Hu F, Hao Z, et al. Efficacy of Early Intensive Blood Pressure Management After Thrombectomy: Protocol for a Randomized Controlled Clinical Trial (IDENTIFY). Neurocrit Care. 2022. PMID: 36329307. doi:10.1007/s12028-022-01618-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。